Join
Live feed
·
INSIDERFilingvia Quantisnow
Athira Pharma Inc. logo

President and CEO Litton Mark James converted options into 108,333 shares and sold $14,108 worth of shares (25,107 units at $0.56), increasing direct ownership by 52% to 242,591 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ATHA· Athira Pharma Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATHA (Athira Pharma Inc.) and more on Quantisnow.